UK investigates possible allergic reactions to Pfizer coronavirus shot
UK investigates two adverse reactions that occurred on the first day of the country's mass vaccination program
Competitive Enterprise Institute senior fellow discusses coronavirus vaccine developments and distribution.
LONDON (AP) — U.K. regulators said Wednesday that people who have a "significant history'' of allergic reactions shouldn't receive the new Pfizer-BioNTech vaccine while they investigate two adverse reactions that occurred on the first day of the country's mass vaccination program.
Professor Stephen Powis, national medical director for the National Health Service in England, said health authorities were acting on a recommendation from the Medical and Healthcare Products Regulatory Agency.
S&P 500, NASDAQ HIT RECORDS AS CORONAVIRUS VACCINE ROLLOUT BEGINS
"As is common with new vaccines the MHRA have advised on a precautionary basis that people with a significant history of allergic reactions do not receive this vaccination after two people with a history of significant allergic reactions responded adversely yesterday,'' Powis said in a statement. "Both are recovering well."
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| PFE | PFIZER INC. | 26.72 | +0.54 | +2.06% |
| BNTX | BIONTECH SE | 111.48 | +5.16 | +4.85% |
The comments came as Dr. June Raine, head of the MHRA, told a Parliamentary committee that regulators had received reports of two allergic reactions from the vaccine.
"We know from the very extensive clinical trials that this wasn't a feature," she said. "But If we need to strengthen our advice, now that we have had this experience with the vulnerable populations, the groups who have been selected as a priority, we get that advice to the field immediately."
A nurse prepares a shot of the Pfizer-BioNTech COVID-19 vaccine at Guy's Hospital in London, Tuesday, Dec. 8, 2020, as the U.K. health authorities rolled out a national mass vaccination program. (AP Photo/Frank Augstein, Pool)
Raine's comments came as part of a general discussion of how her agency will continue to monitor people who receive the vaccine authorized for emergency use last week.